Drugs / [18F]MK-9470
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01462708 | May 2011 → May 2013 | Parkinson disease | Institute for Neurodegenerative Disorders | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]MK-9470 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01462708 ↗ |
| Known as | MK-9470 | “The purpose of this study is to assess MK-9470 Positron Emission Tomography (PET) imaging as a tool to evaluate the activity of the CB-1 receptor in the brain.” NCT01462708 ↗ |